Most beard minoxidil coverage online still cites the Ingprasert 2016 RCT as the primary evidence. The Almutairi 2025 systematic review is the most rigorous piece of evidence now available — it synthesized 19 RCTs and drew conclusions that supersede any individual study. Most competitor sites haven't covered it yet.
What This Study Is
Almutairi AG et al., published in the Journal of Family Medicine and Primary Care in 2025 (Qassim University, Saudi Arabia), is the first systematic review and meta-analysis specifically examining topical minoxidil for facial hair growth. A systematic review synthesizes all available clinical evidence on a topic using standardized methodology; a meta-analysis pools the data statistically. Together, they represent the highest level of evidence in clinical research hierarchy.
The study was also explicitly aimed at equipping family physicians with evidence-based guidance for patients asking about minoxidil for beard growth — acknowledging that this is now a mainstream clinical question that primary care providers need to be ready to answer.
Methodology: How They Found and Selected Studies
The researchers searched four major medical databases — PubMed, Scopus, Web of Science, and the Cochrane Library — for studies published between January 2001 and May 2024. From an initial pool of 302 studies, they applied rigorous inclusion criteria:
- →Randomized controlled trials only (no observational studies, no case reports)
- →Topical minoxidil specifically (not oral)
- →Facial hair / beard as the primary or secondary outcome
- →Placebo-controlled
Result: 19 RCTs met inclusion criteria from the original 302 studies. These 19 trials formed the evidence base for the meta-analysis.
Key Findings
Finding 1: Minoxidil Is Superior to Placebo for Beard Growth
The primary conclusion of the meta-analysis: topical minoxidil outperforms placebo for beard density with statistically significant differences. This was consistent across multiple outcome measures — self-assessed density scores, photographic ratings by blinded evaluators, and direct hair count methodology.
Finding 2: Twice-Daily 3% Protocol Produces the Clearest Results
The most robust evidence was for the twice-daily, 0.5mL of 3% minoxidil liquid protocol — the same protocol used in the Ingprasert 2016 RCT. At 16 weeks, this protocol showed significant differences in self-assessment scores, independent photographic ratings, and hair count vs placebo. This was the RCT with the highest quality evidence in the pool.
Finding 3: The Surprising Side Effect Result
One of the more counterintuitive findings: in some of the included studies, itching and burning were actually reported less frequently in the minoxidil group than in the placebo group. This appears to relate to the vehicle formulations — some placebo vehicles contained irritating ingredients that produced more local reactions than the minoxidil formula itself.
Finding 4: Pruritus and Dermatitis Not Significantly Different Between Groups
Across the pooled studies, the rates of pruritus (itching) and contact dermatitis were not statistically significantly different between minoxidil-treated and placebo-treated subjects. This doesn't mean these side effects don't occur — they do — but at the population level, the difference was not significant enough to be considered a meaningful safety concern in these study populations.
Finding 5: Minimal Serious Adverse Events
No serious systemic adverse events were reported in the included studies at the doses studied. The safety profile of topical minoxidil for beard use — at the concentrations and frequencies tested in clinical trials — was characterized as acceptable for general use.
What This Means for Men Using Minoxidil
The Almutairi 2025 meta-analysis matters for a specific reason: it moves the evidence base from "a few individual studies" to "a systematic synthesis of all available RCT evidence." The conclusion is now formally established in peer-reviewed literature: topical minoxidil works for beard growth, it works better than placebo, and the side effect profile is acceptable.
This is also the study that family physicians can now cite when a patient asks about minoxidil for beard use. The authors explicitly noted this as a goal — filling the gap in clinical guidance for primary care providers who are increasingly being asked this question.
Honest Limitations
Responsible reporting requires noting the limitations the authors themselves acknowledged:
- →Most included studies used 3% concentration — the evidence base for 5% specifically for beards remains thinner.
- →Study durations ranged from 16 weeks to 6 months — long-term (12–24 month) data is limited.
- →Outcome measurement varied across studies, making precise pooling complex.
- →No studies specifically addressed permanence after cessation — a gap the authors noted.
The Evidence Is In. Start Your Protocol.
Nineteen RCTs now confirm what the community knew for years. Happy Head's prescription formula delivers the active ingredient your follicles need.
FAQ
Ingprasert 2016 is a single RCT — strong individual evidence. Almutairi 2025 is a systematic review that includes Ingprasert 2016 among 18 other RCTs and synthesizes all of them. In terms of evidence hierarchy, a systematic review of RCTs sits above any individual RCT. Almutairi 2025 is the stronger piece of evidence — it confirmed and broadened what Ingprasert showed.
No — the inclusion criteria specifically required topical minoxidil studies. Oral minoxidil for beards is covered by the Liu 2025 meta-analysis (27 studies, 2,933 patients), which is a separate body of research. The two meta-analyses together cover the topical and oral evidence bases respectively.
The likely explanation is the vehicle formulation used in placebo comparators. Some placebo vehicles contained ingredients (like certain alcohols or thickeners) that caused local skin reactions. The minoxidil formulas, while containing propylene glycol in liquid form, may have included other buffering excipients that reduced irritation relative to specific placebo formulations. It's a comparison artifact rather than evidence that minoxidil has an anti-itch effect.